Loading...
•
Mar 31, 2022
Taysha Gene Therapies Q1 2022 Earnings Report
Taysha Gene Therapies reported financial results for Q1 2022 and provided a corporate update.
Key Takeaways
Taysha Gene Therapies reported a net loss of $50.1 million for the first quarter of 2022. Research and development expenses were $37.8 million, and general and administrative expenses were $11.5 million. As of March 31, 2022, the company had $96.6 million in cash and cash equivalents.
Initiated clinical development of TSHA-102 for Rett Syndrome under recently approved Clinical Trial Application (CTA) with preliminary Phase 1/2 data expected by year-end 2022.
Received Orphan Drug Designation from the European Commission for TSHA-120 for giant axonal neuropathy (GAN).
Completed commercially representative GMP batch for TSHA-120; regulatory update expected in mid-2022.
Existing cash and cash equivalents, along with full access to the term loan facility, is expected to fund operating expenses and capital requirements into the fourth quarter of 2023.
Taysha Gene Therapies
Taysha Gene Therapies
Forward Guidance
Taysha Gene Therapies anticipates a regulatory update for TSHA-120 in GAN by mid-2022 and preliminary clinical data from the REVEAL study for TSHA-102 in Rett syndrome by year-end 2022.
Positive Outlook
- Regulatory update for TSHA-120 in GAN by mid-2022
- Preliminary clinical data from the REVEAL study for TSHA-102 in Rett syndrome by year-end 2022
- Initiation of clinical development for TSHA-105 in SLC13A5 deficiency
- Continued clinical development of the first-generation construct for CLN7 disease in 2022
- Continued clinical development for TSHA-118 in CLN1 disease